BTK and primary central nervous system lymphoma: Several novel treatments have shown efficacy and overall good tolerance in PCNSL patients, such as ASCT [179–188], BTK inhibitors [56, 189–198] and chimeric antigen receptor T-cells (CAR-T) [199–201].